213 related articles for article (PubMed ID: 38129681)
1. The target atlas for antibody-drug conjugates across solid cancers.
Fang J; Guo L; Zhang Y; Guo Q; Wang M; Wang X
Cancer Gene Ther; 2024 Feb; 31(2):273-284. PubMed ID: 38129681
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
[TBL] [Abstract][Full Text] [Related]
3. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions.
High P; Carmon KS
Cancer Lett; 2023 Jun; 564():216191. PubMed ID: 37100113
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
6. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract][Full Text] [Related]
7. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
8. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
9. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
10. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.
Montero JC; Calvo-Jiménez E; Del Carmen S; Abad M; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Mar; 41(1):106. PubMed ID: 35317825
[TBL] [Abstract][Full Text] [Related]
11. Investigational antibody drug conjugates for solid tumors.
Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
13. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
15. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.
Wei Q; Li P; Yang T; Zhu J; Sun L; Zhang Z; Wang L; Tian X; Chen J; Hu C; Xue J; Ma L; Shimura T; Fang J; Ying J; Guo P; Cheng X
J Hematol Oncol; 2024 Jan; 17(1):1. PubMed ID: 38178200
[TBL] [Abstract][Full Text] [Related]
16. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
17. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for Antibody-Drug Conjugates in Solid Tumors.
Katrini J; Boldrini L; Santoro C; Valenza C; Trapani D; Curigliano G
Mol Cancer Ther; 2024 Apr; 23(4):436-446. PubMed ID: 38363729
[TBL] [Abstract][Full Text] [Related]
19. The antibody-drug conjugate target landscape across a broad range of tumour types.
Moek KL; de Groot DJA; de Vries EGE; Fehrmann RSN
Ann Oncol; 2017 Dec; 28(12):3083-3091. PubMed ID: 29045509
[TBL] [Abstract][Full Text] [Related]
20. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]